Filing Flows › Amneal Pharmaceuticals (AMRX) › Q3 2025
Amneal Pharmaceuticals (AMRX) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
Amneal Pharmaceuticals (AMRX) reported revenue of $785M for the third quarter 2025 (Q3 2025), +12% from a year earlier and +8% from the quarter before. Operating margin was 9.0%, net earnings $18.1M (2.3% of revenue).
Amneal Pharmaceuticals, Q3 2025: revenue $785M (+12% year over year), operating margin 9.0%, net earnings $18.1M, operating cash flow $118M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $785M | +8% | +12% |
| Operating profit | $70.3M | -37% | — |
| Net earnings | $18.1M | -19% | — |
| Operating cash flow | $118M | +41% | -16% |
| Free cash flow | $106M | +74% | -15% |
What changed
Revenue was $784.5M in Q3 2025, up 12% year over year and up 8% from the previous quarter.
Gross margin was 34.9%, down 3.5 points from a year earlier. Operating profit was $70.3M, a 9.0% margin (down 3.7 points year over year). Operating profit fell $18.5M even though revenue rose $82.0M versus a year earlier, so costs grew faster than sales. Operating expenses grew 13% against revenue growth of 12%. The fastest-growing cost line was Other operating costs (+157%). Net earnings were $2.4M.
Operating cash flow was $118.5M (down 16% year over year), 653% of net income including minority interests. Non-cash charges added back $8.2M of share-based compensation. Working capital and other items added $92.1M. Capital expenditures of $12.3M left free cash flow of $106.2M.
Questions
What was Amneal Pharmaceuticals' revenue in the third quarter 2025?
Amneal Pharmaceuticals (AMRX) reported revenue of $785M for the third quarter 2025 (Q3 2025), +12% from a year earlier and +8% from the quarter before.
Was Amneal Pharmaceuticals profitable in the third quarter 2025?
Operating profit was $70.3M (9.0% of revenue) and net earnings $18.1M.